Roche (RHHBY) announced the European Commission has granted marketing authorisation for Tecentriq SC, a PD-L1 cancer immunotherapy for subcutaneous injection. The authorisation applies to all approved indications of Tecentriq IV. Roche said it is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possible.
"We are pleased to introduce the first subcutaneous PD-L1 cancer immunotherapy in Europe," said Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development.
Tecentriq SC was first approved in Great Britain in 2023. The approved indications mirror those of Tecentriq IV.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.